These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 9316848

  • 1. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy.
    Idänpään-Heikkilä JJ, Guilbaud G, Kayser V.
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1366-72. PubMed ID: 9316848
    [Abstract] [Full Text] [Related]

  • 2. In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.
    Idänpään-Heikkilä JJ, Perrot S, Guilbaud G, Kayser V.
    Eur J Pharmacol; 1997 May 01; 325(2-3):155-64. PubMed ID: 9163562
    [Abstract] [Full Text] [Related]

  • 3. The selective cholecystokininB receptor antagonist L-365,260 diminishes the expression of naloxone-induced morphine withdrawal symptoms in normal and neuropathic rats.
    Kayser V, Idänpään-Hekkilä JJ, Christensen D, Guilbaud G.
    Life Sci; 1998 May 01; 62(10):947-52. PubMed ID: 9496717
    [Abstract] [Full Text] [Related]

  • 4. Complete prevention but stimulus-dependent reversion of morphine tolerance by the glycine/NMDA receptor antagonist (+)-HA966 in neuropathic rats.
    Christensen D, Guilbaud G, Kayser V.
    Anesthesiology; 2000 Mar 01; 92(3):786-94. PubMed ID: 10719957
    [Abstract] [Full Text] [Related]

  • 5. The antinociceptive effect of combined systemic administration of morphine and the glycine/NMDA receptor antagonist, (+)-HA966 in a rat model of peripheral neuropathy.
    Christensen D, Idänpään-Heikkilä JJ, Guilbaud G, Kayser V.
    Br J Pharmacol; 1998 Dec 01; 125(8):1641-50. PubMed ID: 9886755
    [Abstract] [Full Text] [Related]

  • 6. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats.
    Nichols ML, Bian D, Ossipov MH, Lai J, Porreca F.
    J Pharmacol Exp Ther; 1995 Dec 01; 275(3):1339-45. PubMed ID: 8531101
    [Abstract] [Full Text] [Related]

  • 7. The enhancement of morphine antinociception by a CCKB receptor antagonist in the rat depends on the phase of inflammation and the intensity of carrageenin-induced hyperalgesia.
    Perrot S, Idänpään-Heikkilä JJ, Guilbaud G, Kayser V.
    Pain; 1998 Feb 01; 74(2-3):269-74. PubMed ID: 9520241
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    Coudoré-Civiale MA, Méen M, Fournié-Zaluski MC, Boucher M, Roques BP, Eschalier A.
    Br J Pharmacol; 2001 May 01; 133(1):179-85. PubMed ID: 11325808
    [Abstract] [Full Text] [Related]

  • 9. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze.
    Kõks S, Soosaar A, Võikar V, Bourin M, Vasar E.
    Neuropeptides; 1999 Feb 01; 33(1):63-9. PubMed ID: 10657473
    [Abstract] [Full Text] [Related]

  • 10. Evidence for a peripheral component in the enhanced antinociceptive effect of a low dose of systemic morphine in rats with peripheral mononeuropathy.
    Kayser V, Lee SH, Guilbaud G.
    Neuroscience; 1995 Jan 01; 64(2):537-45. PubMed ID: 7700537
    [Abstract] [Full Text] [Related]

  • 11. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP.
    J Pharmacol Exp Ther; 1994 Jul 01; 270(1):77-88. PubMed ID: 8035345
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats.
    Coudoré-Civiale MA, Courteix C, Boucher M, Méen M, Fialip J, Eschalier A, Ardid D.
    Neurosci Lett; 2000 May 26; 286(1):37-40. PubMed ID: 10822147
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat.
    Friedrich AE, Gebhart GF.
    J Pharmacol Exp Ther; 2000 Feb 26; 292(2):538-44. PubMed ID: 10640290
    [Abstract] [Full Text] [Related]

  • 19. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.
    Singh L, Oles RJ, Field MJ, Atwal P, Woodruff GN, Hunter JC.
    Br J Pharmacol; 1996 Jul 26; 118(5):1317-25. PubMed ID: 8818359
    [Abstract] [Full Text] [Related]

  • 20. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
    Coudoré-Civiale MA, Courteix C, Fialip J, Boucher M, Eschalier A.
    Pain; 2000 Oct 26; 88(1):15-22. PubMed ID: 11098095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.